A Modern Approach to
Cancer Testing

IONIQ Sciences is at the forefront of early cancer detection

Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages. 

We believe it doesn’t have to be this way. 



Expanding from a
Single Cancer
Test to a
Multi-Cancer Screen

Early detection saves lives and money by detecting cancer at its earliest, most-treatable stages. We're well-positioned to develop a Multi-Cancer Screen by leveraging our lung test, breast test, proprietary technology, substantial bioimpedance database, and our deep clinical experience.

IONIQ Development Pipeline

ProLung Test - FDA Breakthrough Device
Breast Cancer Test
Multi-Cancer Screen
LUNA 3 next-gen, portable platform

Clinical Data

Deep clinical evidence library with data collected from more than 1,400 subjects demonstrating dramatic improvement over today's standard of care

Breakthrough Device

IONIQ's ProLung Test designated “Breakthrough Device” by US FDA for its life-enhancing potential

Premier Clinical Sites

More than 25 premier cancer institutions across 3 continents have participated in our clinical trials

World-Class Advisors

Collaborating with medical and scientific experts

Intellectual Property

Robust, growing intellectual portfolio of 22 issued and filed patents plus expert know-how

Years in the Making

IONIQ Recent News

IONIQ Sciences to Present at BioFuture

Salt Lake City, UT, October 24, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) today announced it is presenting at BioFuture™ and also providing an on-demand company presentation. Mr. Jared Bauer, CEO, will be presenting IONIQ Sciences at BioFuture on November 9, 2022

IONIQ joins Cancer Early Detection Alliance

Salt Lake City, UT, September 8, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is proud to announce it has joined Cancer Early Detection Alliance (CEDA). CEDA’s mission to promote and expand access to quality, equitable care and early cancer detection aligns perfectly

IONIQ recognized as ‘Gamechanger 2022’ award winner

Salt Lake City, UT, August 10, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to be awarded the “Gamechanger Progress Champion 2022” award from ACQ5. The Gamechanger™ Global Awards committee at ACQ5 defines gamechanger as an individual or business that aims

Standards & Certifications

Meet the Team

Proud to be part of BioHive, the Nations Fastest Growing Life Science Hub.

By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving the lives of millions of patients.